To learn more about ChIPmentation, please visit https://diagenode.typeform.com/to/eFXflf
Denville, NJ, USA –
Liège, Belgium (PRWEB) June 14, 2017 — Diagenode, a leading global provider for complete solutions for sample preparation and epigenetics research, has licensed a new technology specific for ChIP-sequencing from the CeMM for low input samples.
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) allows the study of histone modifications and transcription factor binding on a genome-wide scale. However, ChIP from low input, biologically-relevant samples is challenging. Researchers in Christoph Bock’s group at CeMM have developed an efficient alternative to ChIP-seq that addresses these limitations, which they have coined “ChIPmentation.”
In ChIPmentation, ChIP and library preparation for sequencing can be accomplished concurrently using a transposase, that allows the incorporation of sequencing adaptors on the immunoprecipitated chromatin directly. This approach streamlines the ChIP-seq workflow to make the study of chromatin from rare and difficult cell types possible. The lab’s work was published in Nature Methods article “ChIPmentation: fast, robust, low-input ChIP-seq for histones and transcription factors.”
Diagenode’s license terms with the CeMM include acquiring quality procedures and expertise for ChIPmentation libraries and sequencing as well as bioinformatics analysis know-how.
“Our license agreement with the CeMM for ChIPmentation will bring ChIP-seq to new frontiers and reinforces our commitment to furthering epigenetics research,” said Didier Allaer, CEO of Diagenode. “We will be incorporating the ChIPmentation technology into Diagenode’s Epigenomic Profiling Services upon launch later this year. Researchers will finally be able to…